about
Anti-RNA polymerase III antibodies as a risk marker for early gastric antral vascular ectasia (GAVE) in systemic sclerosisMicroRNA-146a in autoimmunity and innate immune responses.Autoantibodies to survival of motor neuron complex in patients with polymyositis: immunoprecipitation of D, E, F, and G proteins without other components of small nuclear ribonucleoproteins.MicroRNAs in rheumatoid arthritis.The Th17 axis in psoriatic disease: pathogenetic and therapeutic implications.Frequent coexistence of anti-topoisomerase I and anti-U1RNP autoantibodies in African American patients associated with mild skin involvement: a retrospective clinical study.MicroRNAs in systemic rheumatic diseasesAtypical clinical presentation of a subset of patients with anti-RNA polymerase III--non-scleroderma cases associated with dominant RNA polymerase I reactivity and nucleolar staining.International cohort study of 73 anti-Ku-positive patients: association of p70/p80 anti-Ku antibodies with joint/bone features and differentiation of disease populations by using principal-components analysis.Autoantibodies to transcription intermediary factor TIF1β associated with dermatomyositis.Anti-MJ/NXP-2 autoantibody specificity in a cohort of adult Italian patients with polymyositis/dermatomyositisA new immunoprecipitation-real time quantitative PCR assay for anti-Th/To and anti-U3RNP antibody detection in systemic sclerosis.MicroRNAs and autoimmunity.Nailfold videocapillaroscopy and serum VEGF levels in scleroderma are associated with internal organ involvementCoexistence of anti-RNA polymerase III and anti-U1RNP antibodies in patients with systemic lupus erythematosus: two cases without features of scleroderma.Gender and ethnicity differences in the prevalence of scleroderma-related autoantibodies.Positive correlation of STAT1 and miR-146a with anemia in patients with systemic lupus erythematosus.Reduced levels of CCL2 and CXCL10 in systemic lupus erythematosus patients under treatment with prednisone, mycophenolate mofetil, or hydroxychloroquine, except in a high STAT1 subset.Elevated signal transducers and activators of transcription 1 correlates with increased C-C motif chemokine ligand 2 and C-X-C motif chemokine 10 levels in peripheral blood of patients with systemic lupus erythematosus.Cardiological features in idiopathic inflammatory myopathies.Common pathways of autoimmune inflammatory myopathies and genetic neuromuscular disorders.Safety issues and concerns of new immunomodulators in rheumatology.A Comprehensive Overview on Myositis-Specific Antibodies: New and Old Biomarkers in Idiopathic Inflammatory Myopathy.Serum antinuclear and extractable nuclear antigen antibody prevalence and associated morbidity and mortality in the general population over 15 years.The Immune Response and the Pathogenesis of Idiopathic Inflammatory Myositis: a Critical Review.Testing for myositis specific autoantibodies: Comparison between line blot and immunoprecipitation assays in 57 myositis sera.PFAPA syndrome and Behçet's disease: a comparison of two medical entities based on the clinical interviews performed by three different specialists.Seronegative reactive spondyloarthritis and the skin.Rpp25 is a major target of autoantibodies to the Th/To complex as measured by a novel chemiluminescent assay.Treatment of lupus skin involvement with quinacrine and hydroxychloroquine.Lupus T cells switched on by DNA hypomethylation via microRNA?Treatment with etanercept in six patients with chronic hepatitis C infection and systemic autoimmune diseases.Suspected and unsuspected factors in the multifaceted immunopathology of viral hepatitis.Role of environmental factors in autoantibody production - importance of a detailed analysis in a small cohort.Evaluation of mortality, disease activity, treatment, clinical and immunological features of adult and late onset systemic Lupus erythematosus.Hepatitis C virus infection and primary Sjögren's syndrome: a clinical and serologic description of 9 patients.Gamma-delta T lymphocytes and 25-hydroxy vitamin D levels as key factors in autoimmunity and inflammation: the case of zoledronic acid-induced acute phase reaction.Anti-RNA polymerase III antibodies: a marker of systemic sclerosis with rapid onset and skin thickening progression.Differential reactivity to IMPDH2 by anti-rods/rings autoantibodies and unresponsiveness to pegylated interferon-alpha/ribavirin therapy in US and Italian HCV patients.Malignancies in Italian patients with systemic sclerosis positive for anti-RNA polymerase III antibodies.
P50
Q28286696-DF02E69A-7600-45F3-9BB5-A575168F5C1DQ34318595-E0E2F30A-8057-4113-ACE0-0FB325A0D134Q35069634-BEF4F937-CAE1-4330-A0C0-6464F4DE862DQ35201337-EFEF9135-5A88-4D1B-AB5E-53FC1E7086EDQ35308947-EE20F441-BE79-47E4-B608-988FFD9BB39DQ35557818-80D3AD49-ED34-4873-8380-BF7CA4CA3950Q35617586-8CC4C42C-D073-437B-BD74-6255778C80F9Q35617650-65CC51E1-B319-4A58-A98F-83F265E79E72Q36084879-A50BD3D6-6F94-434E-9015-4F1F2D8E6210Q36245820-D588FE0C-9D90-4E0B-8E89-34FB380CF13AQ36245898-849AD886-313D-4FC8-97E0-93DEAB07E730Q36246056-231B5AA6-E258-4A2F-A75A-F583B525C645Q36428415-D021B021-017D-49AA-8E6A-984ABCDE4430Q36581926-36DB2FEE-2F7B-432F-BDFF-50F16898EE7BQ36717766-EF11ED53-82A9-48CF-AA57-BC9BD12A7C5EQ36774814-47DC8029-0D50-4B49-AD00-D15D916AF0B6Q37619622-98167F71-769C-4AE6-A4D6-1FEA06CEEC74Q37689745-8B4395C2-FF0C-4E3B-8759-E6B55759125CQ37690029-5ACA79E1-450C-4B26-9EE5-0620F64DF282Q37772062-975FCDE0-7AE5-4E37-AE33-8ABAB805F7BFQ37956169-8216B911-E5EB-43A9-B49E-58C061F98874Q38292111-7D4BA985-56AB-42F5-9B6D-14B5683229C3Q38596370-DEB0A7C7-B227-4BE2-B45D-74EDD3BD6079Q38622492-856539E3-1D35-488E-900B-6DFD05743526Q38700961-2041125A-2E80-4232-8B62-D0CA3D6ED74DQ39975993-9411A704-35C0-4EEC-B74E-C354FDB0594EQ40170236-F7EC3941-FF9E-4846-8CC5-B83276F9F374Q41024976-9EA5802B-8F7C-4E7F-A403-4424A77C4B08Q41532980-BE579064-33A4-41E1-B530-CAE4502F959AQ41938203-B5564084-9EF4-4147-AF7A-276314AB7E49Q42949237-C6A75717-8178-4C84-A71C-B3F156C5AAD6Q42983174-570AD337-78F0-419D-8F88-D0D629004F1EQ42987385-137432D7-8C56-420C-ADA5-535E5CFF3772Q43218594-CC2E8F35-22CA-4D64-AA50-F5182CFA69F0Q43427893-53A494B0-4F3B-4406-A72C-A32908C49A08Q45392131-1665D682-748A-42F1-8D31-5626364FA996Q46751057-F1EAB4AE-F816-427B-8A1C-AD2D9F1EEBF2Q47945742-829DD09F-4A4B-4E8F-A2E0-E7CBFB2476A6Q50550677-883F338A-B5A6-44B8-B3E7-6DBBB9CEDA54Q53256879-EE7E167D-DDF3-4A99-AC40-C176BC36BCC7
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Angela Ceribelli
@ast
Angela Ceribelli
@en
Angela Ceribelli
@es
Angela Ceribelli
@nl
type
label
Angela Ceribelli
@ast
Angela Ceribelli
@en
Angela Ceribelli
@es
Angela Ceribelli
@nl
prefLabel
Angela Ceribelli
@ast
Angela Ceribelli
@en
Angela Ceribelli
@es
Angela Ceribelli
@nl
P106
P1153
24586784500
P21
P31
P496
0000-0001-5116-4724